Grant, C.M., F.H
The future belongs to companies that: Partner with endocrinologists & obesity specialists Build metabolic clinics & patient programs Focus on outcomes, not just prescriptions Trust = Science + Device + Doctor + Ecosystem The brands that understand this early will dominate the next decade of GLP-1 therapy in India
Focusing on such molecules, along with promising therapeutic candidates like Epigallocatechin gallate and tofacitinib, offers encouraging strategies for targeted interventions in RM (Xie et al., 2024)
CrossRef Strategic drug sequencing in hepatocellular carcinoma in the era of chemo-diversity: maximizing the therapeutic benefit of lenvatinib Hideki Iwamoto, Shigeo Shimose, Hironori Koga, Takumi Kawaguchi Journal of Liver Cancer .2026
If these improve alongside general weight loss, tirzepatide is likely benefiting the lipedema component
Tricyclic antidepressants affect several neurotransmitters including serotonin, norepinephrine, and dopamine